1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Astex Pharmaceuticals, Inc. - Strategy and SWOT Report

Astex Pharmaceuticals, Inc. - Strategy and SWOT Report

  • February 2016
  • -
  • MarketLine
  • -
  • 21 pages

Introduction

Astex Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Astex Pharmaceuticals, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Astex Pharmaceuticals, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Astex Pharmaceuticals, Inc. including a breakdown and examination of key business segments

- Intelligence on Astex Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Astex Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Astex Pharmaceuticals, Inc. (Astex or 'the company'), a subsidiary of Otsuka America, Inc., is engaged in the discovery, development and commercialization of cancer therapies in the US. The company is headquartered in Dublin, California. In 2013, Otsuka Pharmaceutical, a wholly-owned subsidiary of Otsuka Holdings, completed the acquisition of Astex. Astex has not disclosed its financial details including revenue, and operating and net profits.

Reasons to Purchase:

- Gain understanding of Astex Pharmaceuticals, Inc. and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Astex Pharmaceuticals, Inc. as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Astex Pharmaceuticals, Inc.’s business structure, strategy and prospects

Table Of Contents

Astex Pharmaceuticals, Inc. - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.